Clinical Trials Browser

Interventional × Rectal Neoplasms × Capecitabine × Clear all

NCT06205485 2026-04-14

NEO-RT

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT02688712 2026-04-13

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT04929028 2026-04-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

NCT06417476 2026-04-13

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT05108428 2026-04-01

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

Phase EARLY_PHASE1 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT04703101 2026-03-30

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Phase 1 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT07281768 2026-03-20

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT07483060 2026-03-19

NG-ST

Phase 4 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT04808323 2026-03-16

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

Phase 1 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT07474103 2026-03-16

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

Phase NA Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Phase 2 Recruiting

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT05731726 2026-03-05

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT07407465 2026-02-17

CHIMERA

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT07113275 2026-02-12

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer

Phase 3 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT04495088 2026-02-02

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT04165772 2026-01-23

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05009069 2026-01-22

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT04095299 2026-01-08

WW3

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT07068763 2026-01-06

mRCAT-E

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT03921684 2026-01-05

Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT02314182 2025-12-19

GRECCAR8

Phase 3 Completed

Gastrointestinal

Rectal Neoplasms

NCT02921256 2025-12-04

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Phase 2 Completed

363 enrolled 16 charts

Gastrointestinal

Rectal Neoplasms

NCT05358704 2025-12-04

Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer

Phase 2 Suspended

Gastrointestinal

Rectal Neoplasms

NCT07239466 2025-11-20

A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT01941641 2025-11-17

Colon Neoadjuvant FOLFOXIRI Study

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT02505750 2025-09-29

OPERA

Phase 3 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT05610163 2025-09-08

JANUS

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT06884670 2025-09-08

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05576480 2025-08-28

SPARC

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT02008656 2025-08-27

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Phase 3 Active not recruiting

831 enrolled 5 FDA

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

NCT04864067 2025-07-01

NOAHS-ARC

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma, Rectal Neoplasms

NCT06507371 2025-06-26

mRCAT-III

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06780787 2025-06-26

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06850090 2025-06-25

Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

Phase 3 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT01804790 2025-06-12

Néofirinox

Phase 3 Completed

Gastrointestinal

Neoplasms, Rectal Neoplasms

NCT06919510 2025-04-09

A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT02945566 2025-03-27

STAR-TREC

Phase 2/3 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT06210971 2025-03-13

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT04406857 2025-02-26

Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer

Phase 1 Terminated

1 enrolled 7 charts

Gastrointestinal

Rectal Neoplasms

NCT04942626 2025-02-21

ACO/ARO/AIO-21

Phase 1 Completed

Gastrointestinal

Rectal Neoplasms

NCT04696757 2025-02-12

NORMANDY

Phase 2 Completed

Gastrointestinal

Rectal Neoplasms

NCT03916510 2025-02-06

CEDAR

Phase 1 Completed

12 enrolled 13 charts

Gastrointestinal

Adenoviridae Infections, Rectal Neoplasms

NCT06204094 2025-01-07

CASINOs

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06751394 2024-12-27

TRACER

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT02861300 2024-12-19

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Phase 1/2 Completed

50 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

NCT05628038 2024-10-01

TORCH-R

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT04246684 2024-09-19

Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Phase 3 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT02514278 2024-08-14

GRECCAR12

Phase 3 Completed

Gastrointestinal

Rectal Neoplasms